ldtЛучевая диагностика и терапияDiagnostic radiology and radiotherapy2079-5343Baltic Medical Education Center10.22328/2079-5343-2019-10-1-86-91ldt-367Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL RESEARCHЛУЧЕВАЯ ДИАГНОСТИКА ИЗМЕНЕНИЙ КОСТНОЙ ТКАНИ ПРИ МЕТАСТАТИЧЕСКОМ РАКЕ ПОЧКИDIAGNOSTIC IMAGING OF THE BONE TISSUE LESIONS AT THE METASTATIC KIDNEY CANCERСеменовД. В.SemyonovD. V.sema.69@mail.ruШирокорадВ. И.ShirokoradB. I.shirokorad@bk.ruМитрофановН. A.MitrofanovH. A.КострицкийС. В.KostritskyC. V.Stas.medic@bk.ruСтарцевВ. Ю.StartsevB. Yu.Городской клинический онкологический диспансерРоссияCity Clinical Oncological ClinicRussian FederationМосковская городская онкологическая больница № 62РоссияMoscow City Oncological Hospital No. 62Russian FederationЛенинградская областная клиническая больницаРоссияLeningrad Regional Clinical HospitalRussian FederationСанкт-Петербургский государственный педиатрический медицинский университетРоссияSt. Petersburg State Pediatric Medical UniversityRussian Federation201909042019018691Copyright © Семенов Д.В., Широкорад В.И., Митрофанов Н.A., Кострицкий С.В., Старцев В.Ю., 20192019Семенов Д.В., Широкорад В.И., Митрофанов Н.A., Кострицкий С.В., Старцев В.Ю.Semyonov D.V., Shirokorad B.I., Mitrofanov H.A., Kostritsky C.V., Startsev B.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://radiag.bmoc-spb.ru/jour/article/view/367

Метастазы в кости встречаются у 20–35% больных генерализованным почечно-клеточным раком (ПКР), при этом преобладают остеокластические (литические) метастазы. Диагностика метастатического поражения скелета при ПКР имеет большое клиническое значение для своевременного лечения, улучшения качества жизни и снижения смертности больных. В статье рассмотрены современные методы лучевой диагностики изменений костной ткани при метастатическом ПКР.

Bone metastases occur in 20–35% of patients with generalized renal cell carcinoma (RCC), and osteoclastic (lytic) metastases prevail. Diagnosis of metastatic lesion of the skeleton during RCC is of clinical importance for timely treatment, improving the quality of life and reducing mortality of patients. The article discusses modern methods of radiation diagnosis of bone tissue changes in metastatic RCC.

рак почкиметастазы в костилучевая диагностикакомпьютерная томографиямагнитнорезонансная томографияпозитронная эмиссионная томографияkidney cancerbone metastasesradiologycomputed tomographymagnetic resonance imagingpositron-emission tomographyReferencesMurai M. Oya M. Renal cell carcinoma: Etiology, incidence and epidemiology // Curr. Opin. Urol. 2004. Vol. 14. Р. 229–233.Murai M. Oya M. Renal cell carcinoma: Etiology, incidence and epidemiology // Curr. Opin. Urol. 2004. Vol. 14. Р. 229–233.Ljungberg B., Campbell S.C., Choi H.Y., Jacqmin D., Lee J.E. et al. The epidemiology of renal cell carcinoma // Eur. Urol. 2011. Vol. 60. Р. 615–621.Ljungberg B., Campbell S.C., Choi H.Y., Jacqmin D., Lee J.E. et al. The epidemiology of renal cell carcinoma // Eur. Urol. 2011. Vol. 60. Р. 615–621.Kozlowski M. Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites // Urol. Clin. North Am. 1994. No. 21 (4). Р. 601–624; 2011. No. 77 (2). Р. 379–384.Kozlowski M. Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites // Urol. Clin. North Am. 1994. No. 21 (4). Р. 601–624; 2011. No. 77 (2). Р. 379–384.Santoni M., Conti A., Procopio G., Porta C., Ibrahim T., Barni S. et al. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? // J. Exp. Clin. Canc. Res. 2015. No. 34 (1).Santoni M., Conti A., Procopio G., Porta C., Ibrahim T., Barni S. et al. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? // J. Exp. Clin. Canc. Res. 2015. No. 34 (1).Kume H., Kakutani S., Yamada Y., Shinohara М., Tominaga Т., Suzuki М. et al. Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors? // J. Urol. 2011. No. 185 (5). Р. 1611–1614.Kume H., Kakutani S., Yamada Y., Shinohara М., Tominaga Т., Suzuki М. et al. Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors? // J. Urol. 2011. No. 185 (5). Р. 1611–1614.Roodman G.D. Mechanisms of bone metastasis // N. Engl. J. Med. 2004. Vol. 350. Р. 1655–1664.Roodman G.D. Mechanisms of bone metastasis // N. Engl. J. Med. 2004. Vol. 350. Р. 1655–1664.Beuselinck B., Oudard S., Rixe O., Wolter P., Blesius A., Ayllon J. et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib // Ann. Oncol. 2010. No. 22 (4). Р. 794–800.Beuselinck B., Oudard S., Rixe O., Wolter P., Blesius A., Ayllon J. et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib // Ann. Oncol. 2010. No. 22 (4). Р. 794–800.Santini D., Perrone G., Roato I., Godio L., Pantano F., Grasso D., Russo A., Vincenzi B., Fratto, M.E. Sabbatini R. et al. Expression pattern of receptor activator of NFkB (RANK) in a series of primary solid tumors and related bone metastases // J. Cell. Physiol. 2011. Vol. 226. Р. 780–784.Santini D., Perrone G., Roato I., Godio L., Pantano F., Grasso D., Russo A., Vincenzi B., Fratto, M.E. Sabbatini R. et al. Expression pattern of receptor activator of NFkB (RANK) in a series of primary solid tumors and related bone metastases // J. Cell. Physiol. 2011. Vol. 226. Р. 780–784.Pal S.K., Nelson R.A., Vogelzang N. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era // PLoS ONE. 2013. Vol. 8. e63341.Pal S.K., Nelson R.A., Vogelzang N. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era // PLoS ONE. 2013. Vol. 8. e63341.Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., Negrier S., Szczylik C., Pili R., Bjarnason G.A. et al. Overall survival and updated results for sunitinib compared with interferon in patients with metastatic renal cell carcinoma // J. Clin. Oncol. 2009. Vol. 27. Р. 3584–3590.Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., Negrier S., Szczylik C., Pili R., Bjarnason G.A. et al. Overall survival and updated results for sunitinib compared with interferon in patients with metastatic renal cell carcinoma // J. Clin. Oncol. 2009. Vol. 27. Р. 3584–3590.Patil S., Figlin R., Hutson T., Michaelson M., Négrier S., Kim S. et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma // Ann. Oncol. 2010. Vol. 22 (2). Р. 295–300.Patil S., Figlin R., Hutson T., Michaelson M., Négrier S., Kim S. et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma // Ann. Oncol. 2010. Vol. 22 (2). Р. 295–300.Schmidt G.P., Reiser M.F., Baur-Melnyk A. Whole-body imaging of the musculoskeletal system: the value of MR imaging // Skeletal Radiol. 2007. Vol. 36. Р. 1109–1119.Schmidt G.P., Reiser M.F., Baur-Melnyk A. Whole-body imaging of the musculoskeletal system: the value of MR imaging // Skeletal Radiol. 2007. Vol. 36. Р. 1109–1119.Wiktora Degi ortopedia i rehabilitacja // Wyd. Nauk. / eds. J. Kruczyński, A. Szulc. Warszawa: PZWL; 2015. 430 р.Wiktora Degi ortopedia i rehabilitacja // Wyd. Nauk. / eds. J. Kruczyński, A. Szulc. Warszawa: PZWL; 2015. 430 р.Mathieu I., Mazy S., Willemart B. et al. Inconclusive triple diagnosis in breast cancer imaging: is there a place for scintimammography? // J. Nucl. Med. Mol. Imaging. 2005. Vol. 46. P. 1574–1581.Mathieu I., Mazy S., Willemart B. et al. Inconclusive triple diagnosis in breast cancer imaging: is there a place for scintimammography? // J. Nucl. Med. Mol. Imaging. 2005. Vol. 46. P. 1574–1581.Groves A.M., Beadsmoore C.J., Cheow H.K., Balan K.K., Courtney H.M., Kaptoge S. et al. Can 16-detector multislice CT exclude skeletal lesions during tumour staging? Implications for the cancer patient // Eur. Radiol. 2006. Vol. 16. Р. 1066–1073.Groves A.M., Beadsmoore C.J., Cheow H.K., Balan K.K., Courtney H.M., Kaptoge S. et al. Can 16-detector multislice CT exclude skeletal lesions during tumour staging? Implications for the cancer patient // Eur. Radiol. 2006. Vol. 16. Р. 1066–1073.Buhmann Kirchhoff S., Becker C., Duerr H.R., Reiser M., BaurMelnyk A. Detection of osseous metastases of the spine: comparison of high resolution multi-detector-CT with MRI // Eur. J. Radiol. 2009. Vol. 69. Р. 567–573.Buhmann Kirchhoff S., Becker C., Duerr H.R., Reiser M., BaurMelnyk A. Detection of osseous metastases of the spine: comparison of high resolution multi-detector-CT with MRI // Eur. J. Radiol. 2009. Vol. 69. Р. 567–573.Sohaib S., Cook G., Allen S., Hughes M., Eisen T., Gore M. Comparison of whole- body MRI and bone scintigraphy in the detection of bone metastases in renal cancer // Br. J. Radiol. 2009. Vol. 82. Р. 632–639.Sohaib S., Cook G., Allen S., Hughes M., Eisen T., Gore M. Comparison of whole- body MRI and bone scintigraphy in the detection of bone metastases in renal cancer // Br. J. Radiol. 2009. Vol. 82. Р. 632–639.Lauenstein T.C., Freudenberg L.S., Goehde S.C., Ruehm S.G., Goyen M., Bosk S., Debatin J.F., Barkhausen J. Whole-body MRI using a rolling table platform for the detection of bone metastases // Eur. Radiol. 2002. Vol. 12. Р. 2091–2099.Lauenstein T.C., Freudenberg L.S., Goehde S.C., Ruehm S.G., Goyen M., Bosk S., Debatin J.F., Barkhausen J. Whole-body MRI using a rolling table platform for the detection of bone metastases // Eur. Radiol. 2002. Vol. 12. Р. 2091–2099.Ghanem N., Altehoefer C., Kelly T., Lohrmann C., Winterer J., Schafer O et al. Whole-body MRI in comparison to skeletal scintigraphy in detection of skeletal metastases in patients with solid tumors. // In Vivo. 2006. Vol. 20. Р. 173–182.Ghanem N., Altehoefer C., Kelly T., Lohrmann C., Winterer J., Schafer O et al. Whole-body MRI in comparison to skeletal scintigraphy in detection of skeletal metastases in patients with solid tumors. // In Vivo. 2006. Vol. 20. Р. 173–182.Adiga G.U., Dutcher J.P., Larkin M., Garl S, Koo J. Characterization of bone metastases in patients with renal cell cancer // B. J. U. Int. 2004. Vol. 93. Р. 1237–1240.Adiga G.U., Dutcher J.P., Larkin M., Garl S, Koo J. Characterization of bone metastases in patients with renal cell cancer // B. J. U. Int. 2004. Vol. 93. Р. 1237–1240.Frat A., Agildere M., Gencoglu A., Cakir B., Akin O., Akcali Z., Aktas A. Value of whole-body turbo short tau inversion recovery magnetic resonance imaging with panoramic table for detecting bone metastases: comparison with 99mTc-methylene diphosphonate scintigraphy // J. Comput. Assist Tomogr. 2006. Vol. 30. Р. 151–156.Frat A., Agildere M., Gencoglu A., Cakir B., Akin O., Akcali Z., Aktas A. Value of whole-body turbo short tau inversion recovery magnetic resonance imaging with panoramic table for detecting bone metastases: comparison with 99mTc-methylene diphosphonate scintigraphy // J. Comput. Assist Tomogr. 2006. Vol. 30. Р. 151–156.Griffin N., Gore M.E., Sohaib S.A. Imaging in metastatic renal cell carcinoma // AJR Am. J. Roentgenol. 2007. Vol. 189. Р. 360–370.Griffin N., Gore M.E., Sohaib S.A. Imaging in metastatic renal cell carcinoma // AJR Am. J. Roentgenol. 2007. Vol. 189. Р. 360–370.Klepzig M., Sauer-Eppel H., Jonas D., Oremek G.M. Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma // Anticancer Res. 2008. Vol. 28. Р. 2443–2446.Klepzig M., Sauer-Eppel H., Jonas D., Oremek G.M. Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma // Anticancer Res. 2008. Vol. 28. Р. 2443–2446.Alcaraz A., Gonzalez-Lopez R., Morote J., de la Piedra, C., Meseguer C., Esteban E., Climent M., Gonzalez-Gragera B., Alvarez-Ossorio J.L., Chirivella I. et al. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The tugamo study // Br. J. Cancer. 2013. Vol. 109. Р. 121–130.Alcaraz A., Gonzalez-Lopez R., Morote J., de la Piedra, C., Meseguer C., Esteban E., Climent M., Gonzalez-Gragera B., Alvarez-Ossorio J.L., Chirivella I. et al. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The tugamo study // Br. J. Cancer. 2013. Vol. 109. Р. 121–130.Pacifici R.T. Сells, osteoblasts, and osteocytes: Interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone // Ann. N. Y. Acad. Sci. 2016. Vol. 1364. Р. 11–24.Pacifici R.T. Сells, osteoblasts, and osteocytes: Interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone // Ann. N. Y. Acad. Sci. 2016. Vol. 1364. Р. 11–24.Waller M.L., Chowdhury F.U. The basic science of nuclear medicine // Orthopaedics and Trauma. 2011. Vol. 25, Nо. 2. P. 91–108.Waller M.L., Chowdhury F.U. The basic science of nuclear medicine // Orthopaedics and Trauma. 2011. Vol. 25, Nо. 2. P. 91–108.Castell F., Cook G.J. Quantitative techniques in 18FDG PET scanning in oncology // Br. J. Cancer. 2008. Nо. 98 (10). P. 1597–1601.Castell F., Cook G.J. Quantitative techniques in 18FDG PET scanning in oncology // Br. J. Cancer. 2008. Nо. 98 (10). P. 1597–1601.Costelloe C.M., Chuang H.H., Madewell J.E. FDG PET for the Detection of Bone Metastases: Sensitivity, Specificity and Comparison with Other Imaging Modalities // PET Clin. 2010. Jul; Vol. 5 (3). Р. 281–295.Costelloe C.M., Chuang H.H., Madewell J.E. FDG PET for the Detection of Bone Metastases: Sensitivity, Specificity and Comparison with Other Imaging Modalities // PET Clin. 2010. Jul; Vol. 5 (3). Р. 281–295.Gerety E.L. et al. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design // Ann. Oncol. 2015. Vol. 26. Р. 2113–2118.Gerety E.L. et al. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design // Ann. Oncol. 2015. Vol. 26. Р. 2113–2118.Huyge V., Garcia C., Vanderstappen A., Alexiou J., Gil T., Flamen P. Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET // Clin. Nucl. Med. 2009. Nо. 34 (7). P. 417–420.Huyge V., Garcia C., Vanderstappen A., Alexiou J., Gil T., Flamen P. Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET // Clin. Nucl. Med. 2009. Nо. 34 (7). P. 417–420.Ito S., Kato K., Ikeda M., Iwano S., Makino N., Tadokoro M. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer // J. Nucl. Med. 2007. Vol. 48 (6). P. 889–895.Ito S., Kato K., Ikeda M., Iwano S., Makino N., Tadokoro M. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer // J. Nucl. Med. 2007. Vol. 48 (6). P. 889–895.Schmidt G.P., Schoenberg S.O., Schmid R., Stahl R., Tiling R., Becker C.R. et al. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT // Eur. Radiol. 2007 Vol. 17. Р. 939–949.Schmidt G.P., Schoenberg S.O., Schmid R., Stahl R., Tiling R., Becker C.R. et al. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT // Eur. Radiol. 2007 Vol. 17. Р. 939–949.Johnston C., Brennan S., Ford S., Eustace S. Whole body MR imaging: applications in oncology // Eur. J. Surg. Oncol. 2006. Vol. 32. Р. 239–246.Johnston C., Brennan S., Ford S., Eustace S. Whole body MR imaging: applications in oncology // Eur. J. Surg. Oncol. 2006. Vol. 32. Р. 239–246.Eustace S., Tello R., DeCarvalho V., Carey J., Wroblicka J.T., Melhem E.R., Yucel E.K. A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases // AJR Am. J. Roentgenol. 1997. Vol. 169. Р. 1655–1661.Eustace S., Tello R., DeCarvalho V., Carey J., Wroblicka J.T., Melhem E.R., Yucel E.K. A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases // AJR Am. J. Roentgenol. 1997. Vol. 169. Р. 1655–1661.Steinborn M.M., Heuck A.F., Tiling R., Bruegel M., Gauger L., Reiser M.F. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system // J. Comput. Assist Tomogr. 1999. Vol. 23. Р. 123–129.Steinborn M.M., Heuck A.F., Tiling R., Bruegel M., Gauger L., Reiser M.F. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system // J. Comput. Assist Tomogr. 1999. Vol. 23. Р. 123–129.Engelhard K., Hollenbach H.P., Wohlfart K., von Imhoff E., Fellner F.A. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer // Eur. Radiol. 2004. Vol. 14. Р. 99–105.Engelhard K., Hollenbach H.P., Wohlfart K., von Imhoff E., Fellner F.A. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer // Eur. Radiol. 2004. Vol. 14. Р. 99–105.Wood S.L., Brown J.E. Skeletal metastasis in renal cell carcinoma: current and future management options // Canc. Treat Rev. 2012. Vol. 38 (4). Р. 284–291.Wood S.L., Brown J.E. Skeletal metastasis in renal cell carcinoma: current and future management options // Canc. Treat Rev. 2012. Vol. 38 (4). Р. 284–291.Seaman E., Goluboff E.T., Ross S., Sawczuk I.S. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma // Urology. 1996. Vol. 48. Р. 692–695.Seaman E., Goluboff E.T., Ross S., Sawczuk I.S. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma // Urology. 1996. Vol. 48. Р. 692–695.Althausen P., Althausen A., Jennings L.C., Mankin H.J. Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma // Cancer. 1997. Vol. 80. Р. 1103–1109.Althausen P., Althausen A., Jennings L.C., Mankin H.J. Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma // Cancer. 1997. Vol. 80. Р. 1103–1109.Koga S., Tsuda S., Nishikido M., Ogawa Y., Hayashi K., Hayashi T., Kanetake H. The diagnostic value of bone scan in patients with renal cell carcinoma // J. Urol. 2001. Vol. 166. Р. 2126–2128.Koga S., Tsuda S., Nishikido M., Ogawa Y., Hayashi K., Hayashi T., Kanetake H. The diagnostic value of bone scan in patients with renal cell carcinoma // J. Urol. 2001. Vol. 166. Р. 2126–2128.Wu H.C., Yen R.F., Shen Y.Y., Kao C.H., Lin C.C., Lee C.C. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas — a preliminary report // J. Cancer Res. Clin. Oncol. 2002. Vol. 128. Р. 503–506.Wu H.C., Yen R.F., Shen Y.Y., Kao C.H., Lin C.C., Lee C.C. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas — a preliminary report // J. Cancer Res. Clin. Oncol. 2002. Vol. 128. Р. 503–506.Jadvar H., Kherbache H.M., Pinski J.K., Conti P.S. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma // Clin. Nephrol. 2003. Dec; Vol. 60 (6). Р. 395–400.Jadvar H., Kherbache H.M., Pinski J.K., Conti P.S. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma // Clin. Nephrol. 2003. Dec; Vol. 60 (6). Р. 395–400.

The authors declare that there are no conflicts of interest present.